Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).
from The Medical News http://ift.tt/1CVHSLm
from The Medical News http://ift.tt/1CVHSLm
No comments:
Post a Comment